Aileron Therapeutics, Inc. (ALRN)

Market Cap	6.68M
Revenue (ttm)	n/a
Net Income (ttm)	-17.48M
Shares Out	4.54M
EPS (ttm)	-3.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,927
Open	1.50
Previous Close	1.52
Day's Range	1.45 - 1.58
52-Week Range	1.12 - 5.64
Beta	2.12
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2023

About ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients wi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 29, 2017
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: ALRN